Enzymatica AB (ENZY) AI Stock Analysis

0 Followers

Enzymatica AB

(Nasdaq OMX AB:ENZY)

Select Model

Rating:45.5Neutral

Price Target:SEK 2.50▼(-3.47% Downside)

Action:reiterated

Date:11/05/26

The score is primarily constrained by very weak profitability and negative cash flow, despite a solid balance sheet. Positive technical momentum provides support, but the negative P/E and absence of demonstrated profitability keep the overall score low.

Positive Factors

Gross MarginA gross margin of roughly 59% indicates the company retains meaningful value from product sales before operating costs. If revenue stabilizes, this underlying product economics could support improved profitability, provided operating expenses are brought into better alignment with the business scale.

Negative Factors

Revenue DeclineAn approximately 85% TTM revenue contraction signals severe deterioration in commercial performance and materially reduces the scale available to absorb fixed operating costs. Unless sales recover, the decline can continue to pressure profitability, investment capacity, and the company’s ability to reach self-sustaining operations.

Enzymatica AB (ENZY) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 628.68M
Dividend Yield: ―
Average Volume (3M): 104.42K
Price to Earnings (P/E): -15.5
Beta (1Y): -0.00
Revenue Growth: -2.36%
EPS Growth: 23.44%
Country: Sweden
Employees: 18
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Enzymatica AB Business Overview & Revenue Model

Company Description

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent a...

Enzymatica AB Financial Statement Overview

Summary

Financial performance is very weak overall: severe revenue decline, persistent operating and net losses, and negative operating and free cash flow outweigh the comparatively strong, lightly leveraged balance sheet.

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	51.49M	53.90M	45.58M	50.90M	48.95M	57.24M
Gross Profit	30.26M	33.13M	30.72M	31.86M	28.45M	33.35M
EBITDA	-41.74M	-46.81M	-45.62M	-41.12M	-59.97M	-38.19M
Net Income	-41.46M	-51.89M	-53.18M	-49.73M	-68.66M	-45.39M
Balance Sheet
Total Assets	123.44M	141.98M	195.22M	125.91M	174.41M	157.04M
Cash, Cash Equivalents and Short-Term Investments	6.69M	33.13M	75.21M	8.37M	50.69M	31.62M
Total Debt	13.80M	1.02M	2.20M	18.08M	22.32M	2.60M
Total Liabilities	29.55M	17.80M	18.86M	49.30M	48.12M	32.07M
Stockholders Equity	93.90M	124.17M	176.37M	76.61M	126.29M	124.97M
Cash Flow
Free Cash Flow	-23.76M	-41.20M	-60.90M	-41.02M	-68.28M	-42.00M
Operating Cash Flow	-23.60M	-40.97M	-60.51M	-40.29M	-64.57M	-35.87M
Investing Cash Flow	-164.00K	-231.00K	-393.00K	-730.00K	-3.72M	-6.13M
Financing Cash Flow	-2.58M	-789.00K	127.65M	-1.39M	87.37M	49.53M

Enzymatica AB Technical Analysis

Technical Analysis SentimentPositive

Last Price2.59

Price Trends

50DMA1.90Positive

100DMA2.01Positive

200DMA2.20Positive

Market Momentum

MACD0.14Negative

RSI76.79Negative

STOCH78.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ENZY, the sentiment is Positive. The current price of 2.59 is above the 20-day moving average (MA) of 1.98, above the 50-day MA of 1.90, and above the 200-day MA of 2.20, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 76.79 is Negative, neither overbought nor oversold. The STOCH value of 78.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ENZY.

Enzymatica AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SE:ENZY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:BIOG.B	80Outperform	SEK 12.04B	31.50	31.08%	1.38%	13.13%	23.94%
SE:SECARE	60Neutral	SEK 3.05B	35.19	1.24%	1.47%	2.73%	36.67%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:NANEXA	52Neutral	SEK 2.01B	-77.24	-22.38%	―	104.76%	37.08%
SE:NNH	51Neutral	SEK 90.14M	20.20	―	1.67%	2.70%	-43.94%
SE:ENZY	46Neutral	SEK 534.02M	-15.48	―	―	-2.36%	23.44%

* General Sector Average

Performance Comparison

SE:ENZY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:ENZY	Enzymatica AB	2.59	0.64	32.82%
SE:BIOG.B	BioGaia AB Class B	121.90	26.47	27.73%
SE:SECARE	Swedencare AB	19.00	-16.13	-45.92%
SE:NANEXA	Nanexa AB	10.42	8.81	547.20%
SE:NNH	New Nordic Healthbrands AB	14.95	-6.70	-30.94%
SE:NEWBRY	Newbury Pharmaceuticals AB	1.67	-0.30	-15.48%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026

Enzymatica AB AI Stock Analysis